6-Chloro-4-Iodopyridin-3-Ol for PROTAC Scaffolds: Orthogonal Halogen Reactivity
Kinetic Differentiation of C4-Iodo vs. C6-Chloro Sites in Sequential Cross-Coupling for PROTAC Linker Assembly
In the construction of proteolysis targeting chimeras (PROTACs), the heterobifunctional architecture demands precise control over sequential bond-forming events. The pyridinol scaffold of 6-chloro-4-iodopyridin-3-ol offers two electronically and sterically distinct halogen handles. The C4 iodine undergoes oxidative addition to palladium(0) with significantly faster kinetics than the C6 chlorine, enabling a chemoselective first coupling without protecting group strategies. This orthogonal reactivity is critical when assembling the warhead–linker–anchor triad, as it minimizes cross-reactivity and simplifies purification. From our field experience, the temperature window for this differentiation is narrow: at 50–60 °C in THF/water mixtures, the iodo site reacts cleanly with aryl boronic acids, while the chloro substituent remains intact. However, we have observed that trace moisture above 500 ppm can accelerate hydrolysis of the active Pd species, leading to premature dechlorination side products. This non-standard parameter—the sensitivity of the C6-Cl bond to hydrolytic Pd(II) species—is rarely discussed in literature but is crucial for scaling up. For R&D managers evaluating 6-chloro-4-iodo-pyridin-3-ol as a PROTAC intermediate, understanding this kinetic window directly impacts yield and purity of the final heterobifunctional molecule.
In medicinal chemistry campaigns, the ability to sequentially functionalize the pyridine core without intermediate deprotection steps accelerates SAR exploration. The C6-chloro site can be subsequently activated under harsher conditions (e.g., Buchwald–Hartwig amination at 100 °C) or via photoredox catalysis. This sequential reactivity pattern is particularly valuable when the linker contains base-sensitive functionalities. Our team has successfully guided multiple clients through the optimization of this two-step sequence, achieving >95% conversion at each stage with minimal dimerization. The key is rigorous control of the Pd/ligand ratio and the use of freshly distilled solvents. For those sourcing 6-chloranyl-4-iodanyl-pyridin-3-ol, we recommend requesting a COA that includes a specific assay for residual palladium, as even ppm levels can catalyze unwanted dehalogenation in subsequent steps.
Residual DMSO Carryover Limits and Solvent Swap Protocols to Prevent Oiling Out During Final Crystallization
One of the most persistent challenges in the downstream processing of PROTAC intermediates is the removal of high-boiling polar aprotic solvents. DMSO, often used in the final coupling step, can tenaciously solvate the pyridinol ring system. In our experience, residual DMSO levels above 0.5% w/w lead to oiling out during the antisolvent crystallization of the PROTAC final product, resulting in poor polymorph control and unacceptable amorphous content. For 6-chloro-4-iodopyridin-3-ol, which has a melting point near 180 °C, the solvent swap from DMSO to a more volatile solvent like ethyl acetate or 2-methyltetrahydrofuran must be executed with care. We have developed a protocol involving azeotropic distillation with heptane at 40–50 mbar, which reduces DMSO to <0.1% without thermal degradation of the iodo substituent. This is a critical quality attribute for any custom synthesis provider, and our batch records consistently demonstrate compliance with this limit.
Another non-standard parameter we monitor is the color of the isolated product. Trace iodine liberated during storage or handling can impart a yellow to brown discoloration, which is unacceptable for pharmaceutical intermediates. Our manufacturing process includes a reductive wash with sodium metabisulfite to ensure a white to off-white crystalline powder. This attention to organoleptic properties is often overlooked by generic suppliers but is essential for maintaining the aesthetic and purity standards of the final drug substance. For those interested in the synthesis route and industrial purity, our technical bulletin on bulk handling 6-chloro-4-iodopyridin-3-ol provides further details on preventing oxidative browning during humid transit.
Batch Assay Tolerances and COA Parameters for Multi-Step Conjugation of 6-Chloro-4-iodopyridin-3-ol
When integrating 6-chloro-4-iodopyridin-3-ol into a multi-step PROTAC synthesis, batch-to-batch consistency is paramount. The critical quality attributes we control and report on every certificate of analysis include assay (HPLC, ≥98.5%), individual impurity (≤0.5%), water content (Karl Fischer, ≤0.2%), and residual solvents (GC, ICH Q3C compliant). However, for PROTAC applications, we also recommend monitoring the ratio of iodo to chloro isomers, as even 0.1% of the 4-chloro-6-iodo regioisomer can lead to mis-coupled products that are difficult to purge. Our manufacturing process, which starts from 3-pyridinol 6-chloro-4-iodo, employs a regioselective iodination that ensures >99.5% isomeric purity. This is a key differentiator from bulk suppliers who may not have the analytical capability to resolve these closely related impurities.
| Parameter | Specification | Typical Value |
|---|---|---|
| Assay (HPLC) | ≥98.5% | 99.2% |
| Isomeric Purity (4-Iodo/6-Chloro) | ≥99.5% | 99.8% |
| Water (KF) | ≤0.2% | 0.08% |
| Residual Pd | ≤10 ppm | <5 ppm |
| Appearance | White to off-white crystalline powder | White crystalline powder |
For R&D managers, the availability of a detailed COA with these parameters reduces the burden of incoming quality control and accelerates process development. We also offer a custom synthesis service for derivatives where the hydroxyl group is protected as a silyl ether or acetate, which can be advantageous for certain coupling conditions. Our team can provide a synthesis route tailored to your specific PROTAC linker requirements, ensuring seamless integration into your medicinal chemistry workflow. For a deeper dive into mitigating catalyst deactivation, our German-language technical note on Beschaffung von 6-Chloro-4-Iodopyridin-3-Ol offers additional insights.
Bulk Packaging and Supply Chain Reliability for PROTAC Scaffold Manufacturing
As PROTAC programs advance from preclinical to clinical stages, the demand for kilogram to multi-kilogram quantities of key intermediates becomes critical. Our supply chain for 6-chloro-4-iodopyridin-3-ol is designed to support this transition seamlessly. We offer standard packaging in 210L steel drums with PTFE-lined closures for bulk shipments, as well as IBC totes for ton-scale orders. The product is classified as a non-hazardous solid under most transport regulations, but we recommend storage at 2–8 °C under nitrogen to prevent oxidative degradation. Our logistics team has extensive experience in managing the cold chain for temperature-sensitive heterocyclic compounds, ensuring that the material arrives at your facility with the same purity as when it left our warehouse.
One often-overlooked aspect of bulk supply is the consistency of particle size distribution, which can affect dissolution rates in large-scale reactors. We control the crystallization process to yield a uniform particle size (D90 < 200 µm), which facilitates rapid dissolution in common organic solvents. This is a non-standard parameter that we have optimized based on feedback from process chemists. For global manufacturers seeking a reliable partner for organic synthesis intermediates, our integrated manufacturing platform from pilot to commercial scale offers a competitive advantage. We maintain safety stock of key raw materials to buffer against supply disruptions, and our dual-site manufacturing strategy ensures business continuity.
Frequently Asked Questions
What is a PROTAC?
A PROTAC (PROteolysis TArgeting Chimera) is a heterobifunctional molecule that recruits an E3 ubiquitin ligase to a target protein, leading to its ubiquitination and subsequent degradation by the proteasome. This modality enables the knockdown of disease-relevant proteins, including those considered “undruggable” by traditional small molecule inhibitors.
How does the orthogonal reactivity of 6-chloro-4-iodopyridin-3-ol benefit PROTAC synthesis?
The C4-iodo and C6-chloro substituents exhibit a significant difference in reactivity toward palladium-catalyzed cross-coupling. The iodo site reacts selectively under mild conditions, allowing for the sequential introduction of the warhead and the E3 ligase ligand without protecting group manipulation. This streamlines the assembly of the PROTAC linker and reduces the number of synthetic steps.
What are the critical residual solvent limits for this intermediate?
For downstream crystallization, residual DMSO must be below 0.5% w/w to prevent oiling out. Our solvent swap protocol achieves <0.1% DMSO. Other solvents like THF and ethyl acetate are controlled to ICH Q3C limits. The COA provides full residual solvent data by GC.
How do you ensure batch-to-batch consistency for multi-step conjugation?
We control the isomeric purity (>99.5%) and assay (>98.5%) of every batch. In addition, we monitor trace metals (Pd, Cu) that could interfere with subsequent catalytic steps. Our quality system includes stability testing under recommended storage conditions to guarantee performance over the shelf life.
Can you provide the compound in protected form?
Yes, we offer custom synthesis of O-protected derivatives (e.g., TBS, MOM) to suit your specific coupling conditions. Please inquire with our technical team for a feasibility assessment.
Sourcing and Technical Support
In the rapidly evolving field of targeted protein degradation, the choice of chemical building blocks can make or break a development timeline. 6-Chloro-4-iodopyridin-3-ol stands out as a versatile scaffold for PROTAC linker assembly, offering orthogonal halogen reactivity that simplifies synthetic routes. By partnering with a manufacturer that understands the nuances of kinetic differentiation, solvent swap protocols, and batch assay tolerances, you can de-risk your supply chain and focus on innovation. Our team brings decades of experience in heterocyclic chemistry and process scale-up, ensuring that you receive a product that meets the stringent demands of medicinal chemistry and beyond. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.